Reneo Pharmaceuticals Inc (OQ:RPHM)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 18575 Jamboree Road, Suite 275-S
IRVINE CA 92612
Tel: N/A
Website: https://reneopharma.com
IR: See website
<
Key People
Michael Grey
Executive Chairman of the Board
Gregory J. Flesher
President, Chief Executive Officer, Director
Michael P. Cruse
Chief Operating Officer
Alejandro Dorenbaum
Chief Medical Officer
Ashley F. Hall
Chief Development Officer
 
Business Overview
Reneo Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The Company's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The Company is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).
Financial Overview
For the three months ended 31 March 2024, Reneo Pharmaceuticals Inc revenues was not reported. Net loss decreased 44% to $8.4M. Lower net loss reflects Research and development - Balancing val decrease of 55% to $4.7M (expense), General and administrative - Balancing v decrease of 15% to $3.8M (expense), Stock-based Compensation in R&D decrease of 47% to $253K (expense).
Employees: 8 as of Mar 31, 2024
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.00M as of Mar 31, 2024
EBITDA (TTM): -$76.35M as of Mar 31, 2024
Net annual income (TTM): -$70.71M as of Mar 31, 2024
Free cash flow (TTM): -$75.70M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 33,420,808 as of May 3, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.